Adicet Bio (ACET) AI Stock Analysis

• Market Cap: $66.22M
• Dividend Yield: N/A
• Average Volume (3M): 105.39K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.51
• Revenue Growth: N/A
• EPS Growth: 25.89%
• Country: US
• Employees: 152
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -2.94
• Shares Outstanding: 9,596,407
• 10 Day Avg. Volume: 90,094
• 30 Day Avg. Volume: 105,393
• PEG Ratio: 0.02
• Price to Book (P/B): 0.36
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.60
• Enterprise Value/Market Cap: 0.64
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -28.55
• Enterprise Value/Ebitda: -0.36
• 1Y Price Target: $38.00
• Price Target Upside: 450.72% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): -32.06
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $6.00 ▼(-13.04% Downside)
• Action: Reiterated Date: 03/13/26
• Date: Action: Reiterated 03/13/26

The score is primarily constrained by weak financial performance (no revenue, large losses, and substantial ongoing cash burn) and bearish technical positioning (below major moving averages with negative MACD). These are partially offset by a supportive low-debt balance sheet and a positive corporate update that includes trial momentum, FDA alignment, and extended runway into 2H 2027.

Positive Factors

Low leverage / solvency

Adicet's low debt-to-equity (~0.09) meaningfully limits near-term solvency risk and preserves financial optionality. For a cash-burning clinical-stage biotech, low leverage reduces refinancing pressure, allows flexibility in structuring partner deals, and lowers near-term bankruptcy risk if development timelines slip.

Negative Factors

No commercial revenue

The absence of recurring product revenue leaves the company fully dependent on external financing and partner milestones. Over the medium term this elevates execution risk: delays or negative trial results would sharply reduce cash inflows and could force dilutive financings or program cuts.

Adicet Bio Business Overview & Revenue Model

Company Description

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like ant...

Read more

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like ant...

How the Company Makes Money

As a clinical-stage biotechnology company, Adicet Bio does not have publicly established, recurring product revenue from marketed therapies (null). Its cash inflows have historically been driven primarily by (1) collaboration and partnership-relat...

Read more

As a clinical-stage biotechnology company, Adicet Bio does not have publicly established, recurring product revenue from marketed therapies (null). Its cash inflows have historically been driven primarily by (1) collaboration and partnership-relat...

Adicet Bio Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	24.99M	9.73M
Gross Profit	-6.38M	0.00	0.00	24.99M	9.73M
EBITDA	-115.73M	-110.65M	-136.53M	-64.70M	-60.41M
Net Income	-116.80M	-117.12M	-142.66M	-69.79M	-62.00M
Balance Sheet
Total Assets	192.35M	220.22M	207.29M	330.69M	338.94M
Cash, Cash Equivalents and Short-Term Investments	158.53M	176.30M	159.71M	257.66M	277.54M
Total Debt	14.74M	17.23M	20.92M	21.02M	20.94M
Total Liabilities	33.15M	33.61M	37.12M	38.35M	35.81M
Stockholders Equity	159.21M	186.61M	170.18M	292.34M	303.13M
Cash Flow
Free Cash Flow	-96.98M	-93.50M	-98.18M	-61.55M	-64.10M
Operating Cash Flow	-95.25M	-92.38M	-93.72M	-44.77M	-51.05M
Investing Cash Flow	2.39M	-119.24M	-4.46M	-16.78M	-2.80M
Financing Cash Flow	75.25M	111.31M	236.00K	41.51M	242.69M

Adicet Bio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACET, the sentiment is Negative. The current price of 6.9 is below the 20-day moving average (MA) of 6.96, below the 50-day MA of 7.26, and below the 200-day MA of 10.11, indicating a bearish trend. The MACD of -0.16 indicates Negative momentum. The RSI at 48.19 is Neutral, neither overbought nor oversold. The STOCH value of 84.96 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ACET.

Adicet Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PMVP	53 Neutral	$69.33M	-0.84	-59.07%	―	―	-58.47%
ARTV	52 Neutral	$180.18M	-1.26	-60.22%	―	-100.00%	-17.10%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
STRO	51 Neutral	$396.79M	-0.51	861.99%	―	-34.36%	-59.98%
GANX	46 Neutral	$78.57M	-5.27	-237.54%	―	―	42.29%
ACET	45 Neutral	$66.22M	-0.50	-82.96%	―	―	25.89%

Adicet Bio Corporate Events